Your session is about to expire
← Back to Search
Baricitinib for Alopecia Areata (BRAVE-AA2 Trial)
BRAVE-AA2 Trial Summary
This trial is testing if baricitinib is a safe and effective treatment for people with severe or very severe AA.
BRAVE-AA2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBRAVE-AA2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 1307 Patients • NCT01710358BRAVE-AA2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: 4 Milligram (mg) Baricitinib
- Group 2: 2 mg Baricitinib
- Group 3: 4 mg Baricitinib Maximum Extended Enrollment (MEE)
- Group 4: 2 mg Baricitinib MEE
- Group 5: Placebo MEE
- Group 6: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Frequently Asked Questions
Are researchers still recruiting patients for this trial?
"The clinical trial is no longer recruiting patients, as reflected on the corresponding clinicaltrials.gov listing which was last updated on 1/24/2022. Although this particular trial has completed recruitment, there are 127 other trials currently looking for participants."
When will Baricitinib be available for public purchase?
"There is both prior clinical data supporting efficacy and multiple rounds of safety testing, so Baricitinib received a score of 3."
Could you tell me how many medical facilities are running this trial?
"There are 35 sites currently enrolling patients for this clinical trial. To reduce the inconvenience of travel, participants should try to select a location nearest to them from Northridge, San Francisco, South Bend or the other 32 locations."
Could elderly individuals be adversely affected by participating in this research?
"The age range for this particular clinical trial is 18 to 70 years old. However, there are 19 other trials available for patients that are below the age of majority and 94 different trials open to senior citizens."
Are there any medical prerequisites for joining this research project?
"To qualify for this research, patients must have alopecia areata and be between 18-70 years old. This study needs approximately 546 individuals to enroll."
What have beenbaricitinib’s most successful treatments?
"Baricitinib is most often given to patients that require hospitalization. However, it has also been used to treat conditions such as coronavirus disease 2019 (covid‑19), ecmo treatment, and rheumatoid arthritis."
Are there any other examples of Baricitinib's efficacy?
"Baricitinib was first studied in 2007 by University of Nebraska Medical Center. Since then, there have been 18299 completed trials worldwide. As of right now, 34 clinical trials are actively recruiting patients with a large number taking place out of Northridge, California."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger